Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.

Click to view original post